FazaClo Outcomes in the Control of Schizophrenia (FOCUS) Study Survey

Completed

• Conditions: Weight Gain; Sialorrhea

• Registration Number: NCT00683891
• Lead Sponsor: Azur Pharma, Inc

Brief Summary

AZUR Pharma has received several reports from practicing psychiatrists prescribing FazaClo showing that FazaClo patients start losing body weight instead of keep gaining it, after being switched from other clozapine products or other atypical antipsychotics treatments. Another important clinical observation reported by doctors is a considerable reduction in hypersalivation when FazaClo administration is compared to other antipsychotic treatments. Based on the findings described above, and on the real need for effective and safer treatments for schizophrenia, AZUR Pharma has decided to design and conduct an observational study in a large number of patients taking FazaClo to prove the received clinical reports from physicians. Better understanding and evaluation of these beneficial findings are necessary to provide physicians information for improved treatment decision.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2008-05-22
• Study First Submitted QC: 2008-05-23
• Study First Posted: 2008-05-26
• Status Verified: 2008-06
• Last Update Submitted: 2008-06-18
• Last Update Posted: 2008-06-19

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• Patients with treatment-resistant schizophrenia currently being treated with Clozaril or generic clozapine for at least 3 months
• Patients with treatment-resistant schizophrenia who failed to respond adequately to treatment with at least 2 courses of standard drug treatments for schizophrenia, either because of insufficient effectiveness or the inability to achieve an effective dose due to intolerable adverse effects from those drugs
• Males and females of 18 years of age or older
• Females of childbearing potential using a reliable form of contraception
• Ability to comply with the required WBC/ANC monitoring schedule
• Ability to follow physician's instructions
• Signed informed consent by patient or legal guardian

Exclusion Criteria

• Phenylketonurics
• Females of childbearing potential not using a reliable form of contraception
• Women who are pregnant or want to become pregnant
• Nursing
• Patients allergic to clozapine or any othe ingredient contained in FazaClo tablets
• Patients who have previously experienced a severe adverse reaction to clozapine
• Patients previously excluded from taking clozapine due to a higher risk of developing white blood cell disorders
• Clinical significant medical condition that the physician believes may increase the patient's risk of participating int he study (e.g., severe cardiac disorder, epilepsy)
• Concomitant medications that may be contraindicated with FazaClo
• Patients who have been taking FazaCLo within the last three months
• Patients unable to comply with the required WBC/ANC monitoring schedule
• Patients unable to follow the physician's instructions
• Patients unable or unwilling to provide Informed Consent

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Clinical changes in body weight in patients with treatment-resistant schizophrenia after initiating treatment with FazaClo
Clinical changes in salivation in patients with treatment-resistant schizophrenia after initiating treatment with FazaClo

Secondary Outcome Measures

Name	Time	Method
Changes in Clinical Global Impression (CGI) scale when compared to baseline

Trial Locations

Locations (2)

Pacific Neuropsychiatric Specialists; 🇺🇸 Costa Mesa, California, United States

Gihwala & Associates; 🇺🇸 Gastonia, North Carolina, United States